32,022 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 32,022 shares of the company’s stock, valued at approximately $717,000.

A number of other institutional investors have also recently bought and sold shares of ELAN. Anchor Investment Management LLC acquired a new position in shares of Elanco Animal Health in the 2nd quarter valued at $29,000. Integrated Wealth Concepts LLC bought a new position in shares of Elanco Animal Health in the 2nd quarter worth $35,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Elanco Animal Health in the 2nd quarter worth $38,000. Root Financial Partners LLC bought a new position in shares of Elanco Animal Health in the 3rd quarter worth $41,000. Finally, Bessemer Group Inc. grew its stake in shares of Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Down 0.4%

Shares of NYSE ELAN opened at $25.65 on Monday. Elanco Animal Health Incorporated has a twelve month low of $19.40 and a twelve month high of $27.98. The stock has a market cap of $12.81 billion, a price-to-earnings ratio of -85.48, a P/E/G ratio of 2.28 and a beta of 1.73. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The company’s fifty day moving average is $23.13 and its 200-day moving average is $23.82.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Friday, November 6th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.07. The business had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.83%. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 1.13 EPS for the current year.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Lawrence Kurzius purchased 40,000 shares of the stock in a transaction on Thursday, August 20th. The stock was bought at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. The trade was a 26.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Harrington purchased 5,000 shares of the stock in a transaction on Wednesday, August 12th. The stock was acquired at an average price of $21.82 per share, with a total value of $109,100.00. Following the completion of the acquisition, the director directly owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 48,998 shares of company stock valued at $1,139,373 in the last three months. Insiders own 1.14% of the company’s stock.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
• Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
• Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

Analysts Set New Price Targets

A number of research firms recently commented on ELAN. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Morgan Stanley reduced their target price on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a report on Thursday, October 29th. Jefferies Financial Group lowered Elanco Animal Health from a “buy” rating to a “hold” rating and decreased their target price for the stock from $31.00 to $24.00 in a research report on Tuesday, October 20th. The Goldman Sachs Group began coverage on Elanco Animal Health in a research note on Friday, October 16th. They issued a “buy” rating and a $32.00 price target for the company. Finally, UBS Group upped their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average price target of $29.33.

Elanco Animal Health Profile

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health.

For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

The company traces its origins to Eli Lilly’s animal health business, established in 1954, and became an independent public company in 2018.